Business Context and Reporting Period
This Form 8-K filing by Ra Medical Systems, Inc. (RMED) reports a material event occurring on December 28, 2020. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Carlsbad, California. The filing addresses the resolution of a pending Department of Justice (DOJ) investigation and a related civil action concerning the marketing of the DABRA laser system.
Key Financial Metrics and Settlement Obligations
This filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins for a specific period. Instead, it details specific financial obligations arising from a legal settlement:
- Initial Payment: $2.5 million due within five business days of full execution.
- Whistleblower Payment: $200,000 for the former employee's expenses and fees.
- Contingent Revenue Payments: If annual revenue exceeds $10 million in fiscal years 2021-2024, additional payments are required: $500,000 (2021), $750,000 (2022), $1 million (2023), and $1.25 million (2024).
- Change in Control Payment: If acquired between 2020-2024, the company must pay $5 million plus 4% of the transaction value (if value exceeds $100 million), capped at a total of $28 million.
- Bankruptcy Contingency: If obligations are avoided via bankruptcy, the company agrees to a claim of $56 million (minus prior change in control payments).
Material Changes and Legal Context
The filing discloses allegations that from May 1, 2017, through October 31, 2019, the company engaged in "Covered Conduct," including:
- Paying illegal remuneration (kickbacks) to physicians to induce use of the DABRA laser system.
- Marketing the DABRA laser system for off-label use in atherectomy procedures despite performance issues (calibration and overheating).
- Failing to report adverse events to the FDA and failing to adhere to Current Good Manufacturing Practices.
The company denies these allegations, and the settlement does not constitute an admission of liability. The settlement resolves federal claims and tentative agreements with participating states.
Outlook, Risks, and Management Commentary
Corporate Integrity Agreement (CIA): The settlement includes a five-year CIA requiring the company to hire a compliance officer and an independent review organization. It imposes strict monitoring, reporting, certification, and training obligations.
Risks and Contingencies:
- Future Liability: The settlement does not release claims under investigation by the SEC or any criminal liability related to the Covered Conduct.
- Exclusion Risk: The OIG has agreed to refrain from excluding the company from federal health care programs only upon full payment and compliance with the CIA.
- Financial Impact: Future cash outflows are contingent on revenue performance and potential acquisition activity.
Investor Verification Checklist
- Verify the execution status of the Settlement Agreement and the timing of the initial $2.5 million payment.
- Review the full text of the Corporate Integrity Agreement (to be filed in the 10-K) to assess operational constraints.
- Monitor the company's revenue projections for 2021-2024 to determine if the $10 million threshold for contingent payments will be triggered.
- Confirm whether the tentative agreements with state attorneys general have been fully executed.
- Check for any ongoing SEC investigations not covered by this settlement.